Skip to main
STRO

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sutro Biopharma is a promising company with a strong track record in developing innovative ADC treatments for cancer and autoimmune disorders. The company's proprietary XpressCF platform and next-generation protein therapeutics show great potential for success. With a strong financial position and continued progress in the clinic, Sutro Biopharma is well-positioned for future growth and success in the healthcare industry.

Bears say

Sutro Biopharma is expected to face competitive challenges in the ADC market due to the consistent, customizable, and tunable features of its proprietary cell-free protein synthesis platform, leading to a presumed premium of $11.26/share for its pipeline. Additionally, STRO-004's β-glu linker with site-specific conjugation and tumor-selective cleavage is projected to improve linker stability and tumor microenvironment targeting, potentially driving higher response rates. However, KOLs have emphasized that linker stability is the key determinant of ADC efficacy and safety, indicating potential risk for Sutro's DAR8 benefit.

STRO has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 9 analysts, STRO has a Buy consensus rating as of Aug 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.